Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GNI Group ( (JP:2160) ) has shared an announcement.
GNI Group’s subsidiary, Cullgen Inc., has successfully completed a Phase 1 clinical trial for CG001419, a promising non-opioid pain treatment. The trial showed that the drug was well tolerated without serious adverse effects, paving the way for a Phase 2 trial in the U.S. in 2026, potentially positioning the company as a leader in non-opioid analgesics.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2311.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on developing innovative therapies. Its primary products and services include novel drug candidates, with a significant market focus on addressing unmet medical needs, particularly in pain management and oncology.
YTD Price Performance: -27.61%
Average Trading Volume: 1,103,008
Technical Sentiment Signal: Hold
Current Market Cap: Yen137.1B
For detailed information about 2160 stock, go to TipRanks’ Stock Analysis page.